Navigation Links
DMH International Selects Beta Partners for TouchPACS
Date:3/14/2013

CORAL SPRINGS, Fla., March 14, 2013 /PRNewswire/ -- DMH International (OTCBB: DMHI), announced that their wholly-owned subsidiary, Touch Medical Solutions, Inc (TMSI) has started the rollout of their medical imaging software suite, TouchPACS. The software is approved by the FDA as a Class II medical device. The first step of the rollout is the process of selecting beta partners to begin using the software.

"The marketing of our PACS software has now begun in earnest," explained Rik J Deitsch, CEO of DMH International. "TouchPACS is now being marketed and demonstrated to hospitals, clinics, radiology centers and physician offices for all of their imaging needs. Our expectation is to develop a dozen beta sites over the next several months," he concluded.

TouchPACS is a cutting edge software suite for the PACS medical imaging market (Picture Archiving and Communications Systems).  The market was valued at approximately $2.8 billion in 2010 and it is expected to grow to over $5.4 billion by 2017, according to MarketResearch.com, a research firm based out of Rockville, Md.

About DMH International.

DMH International, through its subsidiary, Touch Medical Solutions, is a medical software and device company specializing in PACS (Picture Archiving and Communications Systems), EHR (Electronic Hospital records), EMR (Electronic Medical Records), PHR (Personal Health Records), Medical Transcription, and Paperless Medical Office Solutions.  For additional information about Touch Medical Solutions, visit: http://www.dmhintl.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in DMH International's ("the Company's") business plan. The selection of beta sites for TouchPACS should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its present or future financial condition. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Contact:

Bob or Britt Christian

813-996-5658

Champions Financial

bobchristian@championsfinancial.com
brittchristian@championsfinancial.com

 


'/>"/>
SOURCE DMH International
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock
2. HeartWare International, Inc. Announces Public Offering of Common Stock
3. The Societe Internationale dUrologie launches SIU Academy, a powerful new resource for urologists.
4. Mr. William Lerner, Esq. nominated to the Board of Directors of Sanomedics International Holdings, Inc.
5. Dyadic International Reports Profitable 2012 Full Year Financial Results
6. For International Life Sciences, Biotech and Pharmaceutical Events, Top Executives Turn to Global Information
7. DMH International Announces The Launch of TouchPACS
8. DMH International Announces Agreement with MyDICOM and ChangZhou Wealth Information & Technology Co. Ltd
9. Nutrastar International Completes Multi-Year Production Expansion Project Bringing Cordyceps Capacity to 100 Tons
10. DMH International Announces FDA Approval of TouchPACS
11. DMH International Completes Agreement With Wake Forest University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create ... it streamlines the reporting process and provides a familiar interface that does not ...
(Date:4/28/2017)... ... ... sleep affects much more than energy – it also has mental and physical benefits. According ... reaction time, which can increase the risk of having a car accident. , This ... NSF to help you sleep better and feel better:, , Turn ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly ... offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and ... These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... exposed to more adverse experiences than children in the general population. That’s because ... abuse, neglect or other family challenges. While no fault of their own, youth ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection ... improve drug safety and minimize the cost of development. In this webinar, sponsored ... using cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). ...
Breaking Medicine News(10 mins):